Review
Copyright ©The Author(s) 2022.
World J Gastrointest Surg. May 27, 2022; 14(5): 383-396
Published online May 27, 2022. doi: 10.4240/wjgs.v14.i5.383
Figure 3
Figure 3 Milestones in the treatment of neuroendocrine neoplasms[107-114]. US FDA: United States Food and Drug Administration; NEN: Neuroendocrine neoplasm; LAR: Long-acting repeatable; PRRT: Peptide receptor radionuclide therapy.